AHRQ: ‘Super-Utilizers’ account for half of 30-day Medicaid hospital readmissions

 

The readmission rate of super-utilizers, or patients who had four or more admissions during 2012, was nearly six times as high as that of other Medicaid patients, according to a statistical brief from the Agency for Healthcare Research and Quality (AHRQ).

Super-utilizers are a relatively small group of patients who account for a disproportionately large share of hospital services and costs. The brief, written as part of AHRQ’s Healthcare Cost and Utilization Project, specifically found that the 30-day all-cause readmission rate among super-utilizers was 52.4 percent compared with 8.8 percent for other Medicaid patients.

The brief cited the two most common reasons for hospitalization: mood disorders; and schizophrenia and other psychotic disorders.

Read the brief.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.